|
Clinical activity of pan-RAF inhibitor tovorafenib in the registrational pediatric low-grade glioma arm of the phase 2 FIREFLY-1 (PNOC026) study. |
|
|
Employment - Kaiser Permanente (I) |
Stock and Other Ownership Interests - Onconova Therapeutics (I) |
Consulting or Advisory Role - Blueprint Medicines |
Research Funding - Blaze Bioscience (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Epizyme (Inst); Helsinn Therapeutics (Inst); Novartis (Inst); Regeneron (Inst); SpringWorks Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Y-mAbs Therapeutics |
Consulting or Advisory Role - Bayer; EUSA Pharma; Lilly; Ymabs Therapeutics Inc |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Accendatech; Alexion Pharmaceuticals; Amgen; AstraZeneca/Merck; Bayer; Day One Biopharmaceuticals; FivePhusion; Norgine; Novartis |
Research Funding - Accendatech (Inst) |
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
Research Funding - Blaze Bioscience (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Day One Therapeutics; novocure |
|
Consulting or Advisory Role - Bayer |
|
|
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; Day One Therapeutics; Day One Therapeutics |
|
|
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Novartis (Inst); PTC Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Alexion Pharmaceuticals; AstraZeneca/MedImmune; Bayer |
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Novartis; Roche/Genentech |
Speakers' Bureau - Alexion Pharmaceuticals |
Research Funding - AstraZeneca |
Expert Testimony - AstraZeneca |
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; Boehringer Ingelheim; Novartis; Roche/Genentech |
Other Relationship - Abbvie; AstraZeneca/MedImmune; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Day One Therapeutics; Epizyme; Novartis |
|
|
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer; Biogen (I) |
Research Funding - Day One Therapeutics (Inst); Merck (Inst); Novartis (Inst) |
|
|
Employment - Day One Biopharmaceuticals |
Stock and Other Ownership Interests - Day One Biopharmaceuticals |
|
|
Employment - Abbvie; Day One Biopharmaceuticals |
Stock and Other Ownership Interests - Abbvie; Day One Biopharmaceuticals |
Travel, Accommodations, Expenses - Day One Biopharmaceuticals |
|
|
Employment - Amgen; Bayer; Day One Biopharmaceuticals; Loxo; Merck KGaA |
Stock and Other Ownership Interests - Amgen; Bayer; Day One Biopharmaceuticals; Loxo; Merck KGaA |
Patents, Royalties, Other Intellectual Property - US patent 62/318,041 issued to Loxo Oncology. (Inst); US patent 63/251,445 issued to Day One Biopharmaceuticals, Inc. (Inst) |
|
|
Employment - Day One Biopharmaceuticals; Repare Therapeutics |
Stock and Other Ownership Interests - Repare Therapeutics |
Travel, Accommodations, Expenses - Day One Biopharmaceuticals; Repare Therapeutics |
|
|
Stock and Other Ownership Interests - Anteotech |
Consulting or Advisory Role - Alexion Pharmaceuticals; Bayer |
Other Relationship - Boxer Capital |